Cargando…

Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma

BACKGROUND: The treatment landscape for metastatic clear cell renal cell carcinoma (mRCC) is rapidly changing. It is unknown how adoption of new types of therapies may differ by patient age. OBJECTIVE: To compare trends in first-line therapy use for older (≥70 years) and younger (< 70) patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Osterman, Chelsea K., Deal, Allison M., Milowsky, Matthew I., Bjurlin, Marc A., Rose, Tracy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605347/
https://www.ncbi.nlm.nih.gov/pubmed/33195888
http://dx.doi.org/10.3233/KCA-200089
_version_ 1783604291028647936
author Osterman, Chelsea K.
Deal, Allison M.
Milowsky, Matthew I.
Bjurlin, Marc A.
Rose, Tracy L.
author_facet Osterman, Chelsea K.
Deal, Allison M.
Milowsky, Matthew I.
Bjurlin, Marc A.
Rose, Tracy L.
author_sort Osterman, Chelsea K.
collection PubMed
description BACKGROUND: The treatment landscape for metastatic clear cell renal cell carcinoma (mRCC) is rapidly changing. It is unknown how adoption of new types of therapies may differ by patient age. OBJECTIVE: To compare trends in first-line therapy use for older (≥70 years) and younger (< 70) patients with mRCC before and after approval of nivolumab in 2015. METHODS: Using the National Cancer Database, we assessed trends in first-line therapy use by calculating the proportion of patients receiving targeted therapy, immunotherapy, or no systemic therapy by year of diagnosis. Initial systemic treatment was compared for patients diagnosed in 2016 with patients diagnosed in 2011 as a control group prior to nivolumab approval. Multivariable regression analysis was used to evaluate the interaction between year of diagnosis and elderly status for use of first-line immunotherapy or targeted therapy. RESULTS: From 2006 to 2016, the proportion of patients receiving any type of systemic therapy increased from 43.7% to 56.5%. On stratified multivariable regression analysis, older patients diagnosed in 2016 were 17.3 times more likely to receive first-line immunotherapy compared to those diagnosed in 2011, while younger patients were 2.3 times more likely. There was no change in targeted therapy use over this time regardless of patient age. CONCLUSIONS: The rate of adoption of first-line immunotherapy was particularly pronounced for elderly compared to younger patients. While first-line use of immunotherapy may have allowed elderly patients to receive systemic therapy that they otherwise would not, the efficacy of these drugs in elderly patients deserves further study.
format Online
Article
Text
id pubmed-7605347
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-76053472020-11-12 Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma Osterman, Chelsea K. Deal, Allison M. Milowsky, Matthew I. Bjurlin, Marc A. Rose, Tracy L. Kidney Cancer Brief Report BACKGROUND: The treatment landscape for metastatic clear cell renal cell carcinoma (mRCC) is rapidly changing. It is unknown how adoption of new types of therapies may differ by patient age. OBJECTIVE: To compare trends in first-line therapy use for older (≥70 years) and younger (< 70) patients with mRCC before and after approval of nivolumab in 2015. METHODS: Using the National Cancer Database, we assessed trends in first-line therapy use by calculating the proportion of patients receiving targeted therapy, immunotherapy, or no systemic therapy by year of diagnosis. Initial systemic treatment was compared for patients diagnosed in 2016 with patients diagnosed in 2011 as a control group prior to nivolumab approval. Multivariable regression analysis was used to evaluate the interaction between year of diagnosis and elderly status for use of first-line immunotherapy or targeted therapy. RESULTS: From 2006 to 2016, the proportion of patients receiving any type of systemic therapy increased from 43.7% to 56.5%. On stratified multivariable regression analysis, older patients diagnosed in 2016 were 17.3 times more likely to receive first-line immunotherapy compared to those diagnosed in 2011, while younger patients were 2.3 times more likely. There was no change in targeted therapy use over this time regardless of patient age. CONCLUSIONS: The rate of adoption of first-line immunotherapy was particularly pronounced for elderly compared to younger patients. While first-line use of immunotherapy may have allowed elderly patients to receive systemic therapy that they otherwise would not, the efficacy of these drugs in elderly patients deserves further study. IOS Press 2020-09-16 /pmc/articles/PMC7605347/ /pubmed/33195888 http://dx.doi.org/10.3233/KCA-200089 Text en © 2020 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Osterman, Chelsea K.
Deal, Allison M.
Milowsky, Matthew I.
Bjurlin, Marc A.
Rose, Tracy L.
Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
title Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
title_full Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
title_fullStr Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
title_full_unstemmed Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
title_short Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
title_sort trends in initial systemic therapy for elderly patients with metastatic clear cell renal cell carcinoma
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605347/
https://www.ncbi.nlm.nih.gov/pubmed/33195888
http://dx.doi.org/10.3233/KCA-200089
work_keys_str_mv AT ostermanchelseak trendsininitialsystemictherapyforelderlypatientswithmetastaticclearcellrenalcellcarcinoma
AT dealallisonm trendsininitialsystemictherapyforelderlypatientswithmetastaticclearcellrenalcellcarcinoma
AT milowskymatthewi trendsininitialsystemictherapyforelderlypatientswithmetastaticclearcellrenalcellcarcinoma
AT bjurlinmarca trendsininitialsystemictherapyforelderlypatientswithmetastaticclearcellrenalcellcarcinoma
AT rosetracyl trendsininitialsystemictherapyforelderlypatientswithmetastaticclearcellrenalcellcarcinoma